AstraZeneca (LSE:AZN) EU Enhertu Approval Puts Valuation Back In Focus

Why the Enhertu approval matters for AstraZeneca investors

The fresh European Union approval for Enhertu as an adjuvant treatment in HER2 positive early breast cancer puts AstraZeneca (LSE:AZN) in the spotlight as investors reassess its oncology exposure.

For context, AstraZeneca shares trade at £140.66 after a 30 day share price return of 17.24% and a 90 day share price return of 18.76%. The 1 year total shareholder return of 8.99% and 5 year total shareholder return of 74.06% suggest longer term holders have already seen meaningful gains as fresh drug data, reaffirmed 2026 guidance and a packed November conference schedule shape how investors weigh future growth potential against risk.

Scan AstraZeneca alongside other oncology focused opportunities with strong balance sheets using our hand picked list of solid balance sheet and fundamentals (9 results).

AstraZeneca now trades at £140.66 with a 40% gap to one intrinsic value estimate and a 12% discount to the average analyst target. Which reference point best anchors fair value after this latest run?

Most Popular Narrative: 13% Undervalued

On the analyst consensus Narrative on Simply Wall St, AstraZeneca screens at an estimated fair value of £161.08 compared with the last close at £140.66, which raises the question of how much of the broad late stage pipeline and oncology optionality is already baked into that price.

The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management's disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range. This could support high margin revenue growth and earnings as these assets progress from development to launch.

See why 225 investors see AstraZeneca as 13% undervalued.

Result: Fair Value of £161.08 (UNDERVALUED)

Still, AstraZeneca’s oncology story depends heavily on late stage trials and large capital projects. As a result, further clinical setbacks or subpar returns on new manufacturing spend could quickly challenge this undervalued narrative.

Find out about the key risks to this AstraZeneca narrative.

Next Steps

Sentiment across AstraZeneca is mixed, with optimism around assets like Enhertu set against very real clinical and execution risks that investors keep flagging. Act quickly, review both sides of the story, and weigh up the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond AstraZeneca?

If AstraZeneca has sharpened your focus on quality, do not stop here. Broader opportunity often sits just one thoughtful screen away from your current watchlist.

• Target resilient compounding potential by scanning a 4 resilient stocks with low risk scores that aims to keep portfolio drawdowns in check while still leaving room for upside.
• Hunt for quality at a discount by reviewing a curated 16 high quality undervalued stocks that filters for strong fundamentals without relying on hype.
• Stack your income stream by zeroing in on a focused 6 dividend fortresses that highlights higher yielding companies with the financials to support payouts.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com